Research programme: inflammation therapy - Millennium Pharmaceuticals
Alternative Names: MLN 6095Latest Information Update: 05 Nov 2023
At a glance
- Originator Millennium Pharmaceuticals
- Developer Millennium
- Class Small molecules
- Mechanism of Action Prostaglandin D2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 07 Apr 2009 Discontinued - Preclinical for Inflammation in USA (unspecified route)
- 04 Jun 2008 Preclinical development is ongoing
- 14 May 2008 Takeda acquires Millennium